ClinicalTrials.gg
RecruitingNCT06726577Updated Oct 2, 2026

TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis

A Phase 1/2 interventional study of TP04HN106 and Saline in Amyotrophic Lateral Sclerosis, sponsored by Talengen Institute of Life Sciences, Shenzhen, P.R. China.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Talengen Institute of Life Sciences, Shenzhen, P.R. China. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 2, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Amyotrophic Lateral Sclerosis with a site in China — 24 open to participants now, 29 under way, 1 of them phase 3. Amyotrophic Lateral Sclerosis · China.

Planned enrollment
12th of 39
60 · median 24
Started
2026
with 3 others
Phase 1/2
3 of 55
3 open now
Primary completion
2027-01
later than 13 of 28 live
Registered
42nd of 55
by date

Among the 55 studies in Amyotrophic Lateral Sclerosis with a site in China, this one is the 12th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2026, is one of 3 in phase 1/2, reaches primary completion later than 13 of the 28 other live ones, and was the 42nd registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

24 of the 55 studies in Amyotrophic Lateral Sclerosis with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Amyotrophic Lateral Sclerosis with a site in China, or all of them as a file.
02

Study summary

This trial adopts a multicenter, randomized, double-blind, placebo-controlled parallel design.

This experiment is divided into two groups: the experimental drug group and the placebo group. Successful participants will be randomly assigned to the two groups, with an expected enrollment of 60 participants. There will be 30 participants in the experimental drug group and 30 participants in the placebo group. During the treatment period, the experimental drug group received intravenous injections of 0.5mL/kg TP04HN106 each time; The placebo group received intravenous injections of 0.5mL/kg of saline each time. During the extension period, all subjects received intravenous injection of 0.5mL/kg TP04HN106. In the experiment, all subjects received Liraglutide tablets as the standard baseline treatment.

The subjects who were successfully screened in the experiment were enrolled in sequence, and the safety, tolerability, efficacy, and pharmacokinetic characteristics of the experimental drug were evaluated after administration. The entire trial includes a screening period of 1 week, a treatment period of 12 weeks (including 3 treatment cycles, each treatment cycle of 4 weeks), an extension period of 12 weeks (including 3 treatment cycles, each treatment cycle of 4 weeks), and a follow-up period of 4 weeks. In addition, some subjects underwent a 1-week single dose PK study before the start of the treatment period; In addition, during the first treatment cycle of the treatment period, some subjects were selected for multiple dosing PK studies.

We plan to conduct a single dose PK study among 12 subjects, with 6 subjects in the experimental group and 6 subjects in the control group; Multiple dose PK studies were conducted among 12 subjects, with 6 subjects in the experimental group and 6 sujects in the control group. It is not allowed for the same subject to participate in both single dose and multiple dose PK studies simultaneously.

The 1st to 12th subjects planned to be enrolled in the trial will undergo a single dose PK study. After the first dose, venous blood will be collected from the 12 subjects according to the blood sample collection requirements, and their PK characteristics will be evaluated. The observation period for single dose administration is one week. After completing the final blood sample collection and safety assessment, the subjects enter the treatment period, extension period, and follow-up period.

The 13th to 24th subjects planned to be enrolled in the trial will undergo multiple dose PK studies. These 12 subjects will have their venous blood collected according to the blood sample collection requirements during the first treatment cycle of the treatment period, and their PK characteristics will be evaluated. After completing the treatment period, the subjects will enter the extension period and follow-up period.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet the diagnostic criteria for amyotrophic lateral sclerosis (ALS) (Gold Coast Criteria 2020);
  2. Age ≥18 years old, male or female;
  3. The amyotrophic lateral sclerosis Function Rating Scale (ALSFRS-R)of pre-visit subjects should be ≥1 score for dyspnea, upright breathing and respiratory dysfunction;
  4. Pre-randomized subjects received stable dose of riluzole tablets for ≥7 days, and should maintain the treatment until the last study visit;
  5. Voluntarily participate in clinical trials, sign , and understand and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. The subject is known to be allergic to the drug or its ;
  2. The subject has a disease or injury that interferes with functional assessment or threatens life, or is accompanied by a serious irreversible disease of the heart, lung, liver, or brain, or is accompanied by a failure of different organs (for patients with respiratory failure, only patients diagnosed as type I or type II respiratory failure are excluded);
  3. The subject has a major mental illness or cognitive dysfunction;
  4. Patients with a history of secondary or above surgery within one month before the screening period;
  5. The subjects participated in other clinical studies within 1 month;
  6. The subjects are pregnant or lactating women;
  7. Poor compliance or other researchers believe that there are any circumstances that are not suitable for inclusion.

    -

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Experimental drug group

    Drug: TP04HN106

  • Placebo comparator
    Placebo group

    Drug: Saline

Interventions

  • DrugTP04HN106

    During the treatment period, the experimental drug group received intravenous injections of 0.5mL/kg TP04HN106 each time; During the extension period, all subjects received intravenous injection of 0.5mL/kg TP04HN106.

  • DrugSaline

    The placebo group received intravenous injections of 0.83mL/kg of saline each time. In the experiment, all subjects received Liraglutide tablets as the standard baseline treatment.

06

What researchers measure

Primary outcomes

  1. Amyotrophic Lateral Sclerosis Rating Scale (ALSFRS-R)

    The Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) measures the severity of functional disorders. This scale measures three functional domains, namely medullary function, motor function, and respiratory function. The evaluation will consist of 12 questions, with scores ranging from 0 (non functional) to 4 (fully functional), for a total score of 48, which will indicate the highest level of functionality.

    Time frame: Baseline, 10th week

Secondary outcomes

  1. ALSFRS-R

    The Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) measures the severity of functional disorders. This scale measures three functional domains, namely medullary function, motor function, and respiratory function. The evaluation will consist of 12 questions, with scores ranging from 0 (non functional) to 4 (fully functional), for a total score of 48, which will indicate the highest level of functionality.

    Time frame: Baseline, week 2, 6, 12, 14, 18, 22, and 28

  2. Rasch Global Disability Assessment Scale (ROADS) scores

    The Rasch Global Disability Assessment Scale (ROADS) scores is a comprehensive functional impairment assessment scale for amyotrophic lateral sclerosis syndrome. This scale consists of 28 items, arranged in order from the easiest action to the most difficult action, with a total score of 56 points

    Time frame: Baseline, week 2, 6, 10, 12, 14, 18, 22, and 28

  3. FVC%

    The change value/rate of FVC% compared to baseline at weeks 2, 6, 10, 12, 14, 18, 22, and 28;

    Time frame: Basline, weeks 2, 6, 10, 12, 14, 18, 22, and 28

  4. Muscle strength

    Changes in muscle strength from baseline as measured by a handheld dynamometer (HHD) at weeks 2, 6, 10, 12, 14, 18, 22, and 28;

    Time frame: Baseline,week 2, 6, 10, 12, 14, 18, 22, and 28;weeks 2, 6, 10, 12, 14, 18, 22, and 28

  5. Neurofilament light chain level

    Change in the levels of Neurofilament light chain (NFL) in the subjects' venous plasma at week 10 and 22

    Time frame: Baseline,week 10,week 22

  6. CMAP amplitude

    Changes in neuromuscular electrophysiological examination (CMAP amplitude measurement of clinically affected area) relative to baseline at week 10 and 22.

    Time frame: Baseline,week 10,week 22

  7. Incidence of permanent invasive breathing or oxygen assistance/death

    Incidence of permanent invasive breathing or oxygen assistance/death during the trial;

    Time frame: Through study completion, an average of 28 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2027, 7 months after the start.

Of 36 phase 1/2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 7 months is below that.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Jun 2026, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2024
First posted
Dec 10, 2024
StartActual
Jun 4, 2026was May 2026
Primary completionEst.
Jan 2027
CompletionEst.
Apr 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 10, 2026→Jun 4, 2026 (actual)
Oct 2, 2026
Secondary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameFVC%Basline, week 6, 10, 12, 14, 18, 22, and 28 → Basline, weeks 2, 6, 10, 12, 14, 18, 22, and 28
  • DescriptionFVC%: how it is measured was reworded
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Start date May 10, 2026→Jun 4, 2026 (now actual)
    Secondary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameFVC%Basline, week 6, 10, 12, 14, 18, 22, and 28 → Basline, weeks 2, 6, 10, 12, 14, 18, 22, and 28
    • DescriptionFVC%: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06726577
Lead sponsor
Talengen Institute of Life Sciences, Shenzhen, P.R. China.
Responsible party
Sponsor
First posted
Dec 10, 2024
Start date
Jun 4, 2026
Primary completion
Jan 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Doctor Li, Dr
Contact
jnl@talengen-pharma.com
0086-89290018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion